Key result
The benzofuran derivative RT-93 acts as a potent inhibitor of both ClC-Ka and ClC-Kb channels, with apparent dissociation constants of 7.0 µM and 6.0 µM, respectively.
The identification of benzofuran derivatives as high-affinity inhibitors of ClC-Kb channels provides a novel pharmacophore model for the development of new diuretic and antihypertensive drugs.
Answers are grounded in this paper and cite their sources.
Provides novel ClC-K pharmacophore; hypothesis-generating for diuretics, requires validation before clinical consideration.
ClC-Ka and ClC-Kb Cl(-) channels are pivotal for renal salt reabsorption and water balance. There is growing interest in identifying ligands that allow pharmacological interventions aimed to modulate their activity. Starting from available ligands, we followed a rational chemical strategy, accompanied by computational modeling and electrophysiological techniques, to identify the molecular requisites for binding to a blocking or to an activating binding site on ClC-Ka. The major molecular determinant that distinguishes activators from blockers is the level of planarity of the aromatic portions of the molecules: only molecules with perfectly coplanar aromatic groups display potentiating activity. Combining several molecular features of various CLC-K ligands, we discovered that phenyl-benzofuran carboxylic acid derivatives yield the most potent ClC-Ka inhibitors so far described (affinity <10 microM). The increase in affinity compared with 3-phenyl-2-p-chlorophenoxy-propionic acid (3-phenyl-CPP) stems primarily from the conformational constraint provided by the phenyl-benzofuran ring. Several other key structural elements for high blocking potency were identified through a detailed structure-activity relationship study. Surprisingly, some benzofuran-based drugs inhibit ClC-Kb with a similar affinity of <10 microM, thus representing the first inhibitors for this CLC-K isoform identified so far. Based on our data, we established a pharmacophore model that will be useful for the development of drugs targeting CLC-K channels.
No takes yet. Share an insight, caveat, or question.
Liantonio et al. (2008) studied CLC-K channel modulation. Benzofuran derivatives (e.g., RT-93) vs. Control (absence of drug) was evaluated on Apparent dissociation constant (Kd) for channel block. The benzofuran derivative RT-93 acts as a potent inhibitor of both ClC-Ka and ClC-Kb channels, with apparent dissociation constants of 7.0 µM and 6.0 µM, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: